To Salt or Not to Salt — That Is the Question

An Evidence-Based Position on Dietary Sodium Intake

Prepared
Lev Neymotin, PhD

Abstract

This paper presents an evidence-based position on optimal dietary sodium intake and contrasts it with commonly promoted low-sodium recommendations exemplified by current Google AI guidance.

The **mainstream automated recommendation**, reflected in Google AI results, continues to promote **universal sodium restriction below 2,000–2,300 mg/day**, with additional targets of **<1,500 mg/day** for older adults, African Americans, and individuals with hypertension or diabetes. These values mirror decades-old public-health messaging rather than outcome-based clinical evidence. The underlying rationale is the well-established relationship between sodium intake and blood pressure. However, these recommendations do **not** account for long-term cardiovascular and mortality data, nor for the physiological consequences of sustained very-low sodium intake.

In contrast, the present paper conducts a comprehensive review of **physiology**, **randomized trials**, and **large prospective cohorts** and concludes that **the safest sodium intake for most adults is 3–5 g/day**, with **increased risk** at both **very high (>5–6 g/day)** and **very low (<2 g/day)** intakes. Large population studies and meta-analyses consistently demonstrate a **U-shaped association**, with elevated cardiovascular and all-cause mortality at extremely low sodium consumption—contradicting the universal-restriction framework reflected in Google AI outputs.

This juxtaposition highlights a critical divergence: **Google AI and similar automated systems replicate the older, guideline-based low-salt paradigm, while modern data support a more physiologically grounded moderate-intake model**. The present paper adopts the latter as the authoritative, evidence-aligned standard.

1. Background and Rationale

Global and national bodies—including the World Health Organization (WHO), American Heart Association (AHA), and U.S. federal agencies—currently recommend **sodium intake below about 2,000–2,300 mg/day** (under 5–6 g of salt) for adults, with some guidelines promoting 1,500 mg/day as an "ideal" target.

These recommendations are grounded largely in:

- Experimental and clinical evidence that increasing sodium raises blood pressure in a dose-dependent way.
- Observational associations between higher blood pressure and increased risk of stroke, myocardial infarction, and heart failure.

However, in the last 10–15 years, several large prospective cohort studies and meta-analyses have reported:

- **Increased risk at high sodium intakes** (typically >5–6 g/day).
- **Increased risk at very low sodium intakes** (typically <2–2.5 g/day).
- **Lowest risk in a moderate range of approximately 3–5 g/day**.

These findings challenge the older assumption that 'lower is always better' and necessitate a clear, updated position.

Despite emerging evidence indicating a U-shaped risk curve, many public-health recommendations continue to emphasize universal sodium restriction. This persistence reflects historical guideline inertia, focus on blood-pressure surrogates, and the absence of long-term randomized trials comparing moderate versus very low intake ranges.

These limitations set the stage for comparing older simplified guideline messaging with more recent outcome-based evidence.

2. Scope and Methodological Approach

This position paper integrates:

1. **Randomized controlled trials (RCTs)** assessing salt reduction and intermediate outcomes (principally blood pressure).
2. **Prospective cohort studies** examining sodium intake (usually via urinary sodium excretion) and hard outcomes: cardiovascular disease (CVD), stroke, heart failure, and all-cause mortality.
3. **Meta-analyses and critical reviews** evaluating dose–response patterns, including proposed U- or J-shaped curves.

We treat sodium intake as a **continuous exposure** and focus on outcome-based evidence, not solely on blood-pressure surrogates.

3. Physiological Role of Sodium and Mechanisms of Harm at Extremes

3.1 Normal physiology

Sodium is essential for:

- Maintenance of extracellular fluid volume and osmolarity
- Nerve conduction and muscle contraction
- Blood pressure regulation

Homeostasis is achieved via kidney function and multiple hormonal systems, particularly the **renin–angiotensin–aldosterone system (RAAS)** and the **sympathetic nervous system**.

3.2 Mechanisms at high sodium intake

At sustained high sodium intake:

- **Plasma volume and arterial pressure rise**, especially in salt-sensitive individuals.
- Kidneys must excrete larger sodium loads, increasing glomerular pressure.
- Persistent pressure load contributes to:
    - Left ventricular hypertrophy
    - Stroke and heart failure
    - Progression of kidney disease

These biological pathways support the strong, well-documented linear relationship between sodium intake and blood pressure.

3.3 Mechanisms at very low sodium intake

At habitually very low sodium intake (≈<2 g/day):

- RAAS activation increases, with higher **renin and aldosterone** levels.
- **Sympathetic activity** and **norepinephrine** rise.
- There is evidence of **worsened insulin sensitivity**, adverse changes in lipids, and potential endothelial dysfunction.

These compensatory responses may offset, or even outweigh, the benefits of modest additional blood-pressure reduction, helping explain why very low sodium intake is often associated with **higher—not lower—cardiovascular risk** in long-term studies.

4. Evidence from Randomized Trials

RCTs consistently show:

- **Reducing sodium intake lowers blood pressure**, with roughly linear dose–response across common intake levels.
- The effect size is larger in:
    - Hypertensive patients
    - Older adults
    - Salt-sensitive subgroups

Meta-analyses of sodium reduction trials confirm significant, clinically relevant BP reduction, particularly when moving from very high to moderate intake levels. PMC+1

Limitations:

- Most RCTs are relatively short-term (weeks to months).
- They are typically powered for blood pressure, not hard endpoints like stroke or mortality.
- Very few have compared **moderate** vs **very low** sodium intake for long enough to evaluate long-term harms of chronic RAAS activation.

Conclusion from RCTs:
Sodium reduction **lowers blood pressure**, especially when baseline intake is high and/or the patient is hypertensive. RCTs, however, do not conclusively define the long-term optimal intake range for mortality and CVD events.

5. Evidence from Cohort Studies and Meta-Analyses

5.1 PURE and related large cohorts

The Prospective Urban Rural Epidemiology (PURE) study and related analyses examined over 100,000 people across multiple countries, using urinary sodium excretion estimates as a proxy for intake. Key findings:

- **Higher risk at high intake:** Communities with mean sodium intake above ~5 g/day showed increasing rates of stroke and major cardiovascular events.
- **Higher risk at very low intake:** Individuals consuming less than ~3 g/day had higher cardiovascular and all-cause mortality.
- **Lowest risk:** Observed in the range of approximately **3–5 g of sodium per day**, the "sweet spot" for overall cardiovascular outcomes.

5.2 Meta-analyses showing U- or J-shaped association

Several meta-analyses of prospective cohorts report that both **low** and **high** sodium intakes are associated with increased mortality, consistent with a **U- or J-shaped association** between sodium and health outcomes.

- One influential meta-analysis noted increased mortality at intakes below ~2.7 g/day and above ~5 g/day, with **lowest risk around the middle** of that range.
- A more recent synthesis found that while high sodium intake is clearly associated with increased CVD risk, **the relation between low sodium intake and mortality remains highly contentious**, but multiple large datasets still show relative risk elevation at very low levels.

5.3 Critiques and methodologic issues

Concerns raised about these observational studies include:

- **Measurement error** in sodium intake (use of spot urine vs multiple 24-hour collections).

- **Reverse causality**: sicker individuals may eat less food (and less sodium), inflating risk estimates at low intake.
- **Residual confounding**: dietary patterns, socioeconomic status, and other factors may influence both sodium intake and outcomes.

Nevertheless, the **convergent observation of higher risk at both extremes** across diverse cohorts, methods, and populations strengthens the plausibility of a U-shaped relationship.



Figure X. Evidence-Based U-Shaped Sodium–Risk Curve Compared with WHO/AHA Guideline Monotonic Model.

This figure contrasts two fundamentally different conceptual models of cardiovascular risk as a function of daily sodium intake. The **orange curve** represents the evidence-based U-shaped relationship supported by large prospective cohort studies and consistent with known physiological mechanisms: cardiovascular risk is **elevated at both very low (<2 g/day)** and **very high (>6 g/day)** sodium intake, with the **lowest risk observed in the moderate "optimal zone" of 3–5 g/day**.

The **dashed curve** reflects the **traditional WHO/AHA guideline paradigm**, in which risk **increases monotonically** with higher sodium intake and very low intake is assumed to be universally beneficial. Unlike the evidence-based curve, the guideline model **does not account for increased risk at very low sodium intake**, nor for RAAS activation, sympathetic stimulation, or metabolic effects associated with chronic sodium restriction.

6. Integrated Risk Model

Synthesizing:

1. **Linear BP response to sodium** (more sodium, higher BP).
2. **Non-linear outcome data** (increased risk at both very low and very high intakes).
3. **Physiologic mechanisms at extremes** (volume overload vs RAAS/sympathetic overdrive).

We arrive at the following **integrated model**:

- **Very low intake (<2 g/day)**
  - Lower BP, but significant neurohormonal activation and possible metabolic and vascular harms.
  - Net effect in large cohorts: **no clear benefit and potential harm**.
- **Low to moderate intake (~2–3 g/day)**
  - Appropriate for patients with hypertension, heart failure, or CKD where BP and volume control are priorities, under medical supervision.
- **Moderate intake (~3–5 g/day)**
  - Aligns with lowest risk range in multiple large cohorts.
  - Represents a pragmatic and physiologically comfortable intake for most healthy adults.
- **High intake (>5–6 g/day, especially >7 g/day)**
  - Increasing risk of hypertension, stroke, and heart failure; risk rises with higher levels and with salt sensitivity.

This model is **consistent with physiologic data, clinical experience, and the bulk of observational outcome data**.

7. Proposed Intake Targets

7.1 General, healthy adult population (normal renal and cardiac function)

- **Recommended target range:**
  3–5 grams of sodium per day (~7.5–12.5 grams of salt).
- **Rationale:**
  - Corresponds to lowest cardiovascular and mortality risk in large cohorts.
  - Avoids RAAS/sympathetic activation associated with very low intake.
  - Avoids volume and pressure load associated with very high intake.
  - Represents a pragmatic and physiologically comfortable intake for most healthy adults.

(See Figure X for a graphical depiction of risk across sodium intake levels.)

7.2 Adults with hypertension (without advanced HF or CKD)

- **Recommended target:**
  2–3 grams of sodium per day.
- **Rationale:**
  - Additional BP reduction is beneficial in this group.
  - This level remains above the “very low” range where harm is observed in some studies.
  - Should be individualized based on BP control, medications, and patient tolerance.

7.3 Heart failure (HF)

- **Recommended target (default):**
  2–3 grams/day, individualized.
- **Comments:**
  - Extreme restriction (<1.5–2 g/day) is commonly recommended but **evidence is mixed**, and overly aggressive restriction can worsen neurohormonal activation and quality of life.

- Targets should be supervised by cardiology/heart failure specialists, adjusted for congestion status, diuretic use, and symptoms.

7.4 Chronic kidney disease (CKD)

- **Recommended target:**
  2–3 grams/day as a pragmatic starting point.
- **Comments:**
  - Helps with blood pressure and proteinuria control.
  - Very low intakes (<2 g/day) may be considered in selected patients with close monitoring.

7.5 Children

- Sodium recommendations for children should be **scaled down by energy requirements**, broadly aligned with WHO guidance, with emphasis on avoiding high-sodium processed foods rather than micromanaging exact grams.

8. Practical Implementation and Public-Health Messaging

8.1 Core messages to the public

1. **Most people should live in the middle**:
   Not "as low as possible," not "salt is harmless," but a **middle zone** of intake.
2. **Reduce obvious excesses**:
   Processed foods, fast food, instant soups, processed meats, and salty snacks are the major sources of high sodium intake in industrialized diets.
3. **Improve potassium and overall diet quality**:
   High potassium intake (fruits, vegetables, legumes) improves sodium–potassium balance and is independently associated with reduced CVD risk.
4. **Salt sensitivity varies**:
   Some people's blood pressure rises sharply with salt, others much less. While population guidance must be simple, clinicians should individualize.

8.2 Guidance for clinicians

- **Assess baseline risk** (BP, CVD, kidney function, heart failure).
- **Estimate dietary sodium** (dietary history, occasional urinary sodium if needed).
- **Set a target range** based on the framework above.
- **Monitor response** (BP, symptoms, lab values).
- Avoid uncritical adoption of **"<1.5 g/day for everyone"** without considering the patient's overall status and the emerging U-shaped risk evidence.

9. Policy Implications

1. **Re-evaluate universal very-low sodium targets for whole populations.**
   Current recommendations for ≤2,000–2,300 mg/day for all adults should be reconsidered in light of outcome data suggesting potential harm at very low intakes in free-living populations.
2. **Prioritize reduction of extreme high intakes.**
   In many countries, actual mean intake exceeds 4–5 g/day; targeted reduction toward ~3–5 g/day will likely yield the greatest public-health benefit.
3. **Shift focus from "salt alone" to overall dietary patterns.**
   Policies should emphasize:
   - Less ultra-processed food
   - More potassium-rich whole foods
   - Improved labeling and education

4. **Support research that includes moderate vs very low sodium comparisons.**
   Long-term trials comparing ~2 g vs ~3–5 g/day, particularly in high-risk groups, are needed to refine thresholds.

10. Remaining Uncertainties and Research Needs

Despite a clear enough pattern to support the recommendations above, several uncertainties remain:

- The exact **shape and steepness** of the U-curve across different ethnic, genetic, and clinical subgroups.
- Optimal sodium levels in **advanced HF and CKD**, where competing risks (congestion vs RAAS activation) are delicate.
- Interactions between sodium, potassium, and other dietary factors (e.g., ultra-processed foods, sugar, alcohol).
- Best strategies to **measure sodium reliably** in large populations (better biomarkers and standardized methods).

These uncertainties do not invalidate a central, pragmatic intake recommendation; rather, they define the agenda for future refinement.

Accordingly, this evidence-based position should serve as the updated guiding framework for clinicians, researchers, public-health leaders, and information systems that continue to rely on outdated sodium guidance.

11. Final Position Statement

On the basis of current evidence from physiology, randomized trials, and large prospective observational studies, we adopt the following clear and authoritative position:

1. **For most adults with normal kidney and heart function, the optimal sodium intake range is approximately 3–5 grams per day** (about 7.5–12.5 grams of salt).
2. **Regular intake substantially above 5–6 grams per day increases the risk of hypertension, stroke, heart failure, and cardiovascular death**, particularly in salt-sensitive or otherwise high-risk individuals. The Lancet+1
3. **Chronic intake below ~2 grams per day is not advisable for the general population**, as multiple large cohort studies associate very low sodium intake with increased cardiovascular and all-cause mortality, likely due to neurohormonal and metabolic consequences of chronic sodium deprivation. New England Journal of Medicine+2PubMed+2
4. **For individuals with hypertension, heart failure, or chronic kidney disease, a target of 2–3 grams of sodium per day, individualized and clinically monitored, is reasonable and evidence-aligned.**
5. **Population-wide policy should move away from "as low as possible" salt messaging** and instead promote:
   - Avoidance of very high sodium intakes,
   - Avoidance of habitual very low intakes in the general population,
   - Emphasis on overall diet quality and sodium–potassium balance.

In practical terms:
Neither fear of salt nor indifference to it is justified. The consistent evidence supports a physiologic middle ground: avoid extremes, aim for 3–5 grams of sodium per day for most adults, and 2–3 grams per day for those with hypertension, heart failure, or kidney disease, under clinical guidance. These intake levels reflect the lowest observed risk for cardiovascular events and mortality in large, prospective, outcome-based cohort analyses.

This framework provides a stable, coherent basis for clinical practice, public-health policy, and patient education, and can be used today as a guide for both medical and general communities.

Conclusion

Two fundamentally different approaches to sodium guidance now coexist in the public domain.

Automated health recommendations, including those exemplified by Google AI, continue to promote **across-the-board sodium restriction to <2,300 mg/day**, with many subgroups urged to limit intake to **<1,500 mg/day**. These recommendations echo historical public-health positions based primarily on the relationship between sodium and blood pressure. However, they do **not** incorporate the last decade of outcome-based evidence and largely ignore the physiological consequences of long-term sodium deprivation.

In contrast, the present evidence review—grounded in physiological mechanisms, randomized blood-pressure trials, and robust observational outcome data—demonstrates that **the optimal sodium intake for the general population lies in the moderate range of 3–5 grams/day**, where cardiovascular and mortality risks are consistently lowest. Both **very high** (>5–6 g/day) and **very low** (<2 g/day) sodium intakes are associated with increased risk. The U-shaped risk curve is reinforced by multiple large cohorts, including PURE and NHANES, and is compatible with known compensatory hormonal responses at intake extremes.

Therefore, the authoritative position supported by the totality of evidence is unequivocal:
Universal low-sodium targets are not justified. Optimal population health is achieved not by pushing sodium intake to the lowest possible value, but by avoiding both extremes and maintaining a physiologically natural intake of approximately 3–5 grams per day for healthy adults.

Older “low-salt for all” guidance persists largely due to historical inertia and its simplicity for policy messaging—not because it reflects the actual distribution of cardiovascular outcomes across sodium intake levels. As long as automated systems reiterate outdated or incomplete guidelines, clear scientifically grounded analyses—such as the present work—remain essential for clinicians, policymakers, and the public.